Glaxo Canada loses transfer pricing case
June 12, 2008
Pharmaceuticals company could face massive tax bill
A ruling in the Tax Court of Canada this week against GlaxoSmithKline Canada could cost the pharmaceuticals company millions of dollars in back taxes, penalties and interest.
The rest of this article is available to subscribers only. Subscribe today for full access to this article.
This article is not available to current free trialists.
If you are already a paid subscriber, please log in below to access the rest of this article.